DEF: Jaguar Health Sets 2026 Annual Meeting Agenda

Jaguar Health, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 22, 2026, to address director elections, auditor ratification, and significant equity issuances.

Summary

• Jaguar Health, Inc. is holding its 2026 Annual Meeting of Stockholders on May 22, 2026, in San Francisco, California.
• Key proposals include the election of a Class II director, ratification of RBSM LLP as the independent auditor for fiscal year 2026, and approval for the issuance of over 19.99% of the company's common stock to C/M Capital Master Fund, LP under two separate agreements: an Equity Line of Credit (ELOC) Agreement for up to $40 million and a Preferred Stock Purchase Agreement for $2.4 million in Series P Preferred Stock.
• Stockholders will also vote on granting the company discretionary authority to adjourn the meeting if necessary to solicit additional proxies for proposals 3 and 4.
• The record date for determining stockholders entitled to vote is April 15, 2026, with 14,044,277 shares of common stock and 1,241,927.7 shares of Series O Convertible Preferred Stock outstanding as of that date.
• The company is seeking stockholder approval for these issuances due to Nasdaq Listing Rule 5635(d), which requires such approval for issuances exceeding 19.99% of outstanding shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant potential for dilution to existing shareholders from the proposed equity financings, despite the necessity of capital for the company's operations.

Positives

• The company is proactively seeking stockholder approval for significant capital-raising initiatives, demonstrating transparency.
• The proposed ELOC agreement provides a potential source of up to $40 million in capital, which could be crucial for working capital and general corporate purposes.
• The ratification of RBSM LLP as the independent auditor suggests continuity and confidence in the firm's services.
• The board of directors unanimously recommends voting FOR all proposed resolutions, indicating board alignment.

Negatives

• The proposed issuances to C/M Capital, if fully realized, will result in significant dilution to existing common stockholders, potentially impacting voting power and economic rights.
• The ELOC agreement involves selling shares at a discount to market prices, which could further depress the stock price.
• The Series P Preferred Stock accrues an 8% annual dividend and has redemption rights, which could lead to further dilution if redeemed for common stock.
• The company has a history of reverse stock splits, indicating potential past struggles with maintaining share price and listing requirements.

Risks

• Significant dilution to existing shareholders due to the potential issuance of a large number of shares under the ELOC and Preferred Stock agreements.
• Potential decrease in stock price due to the issuance of shares at a discount and the resale of shares by C/M Capital.
• The company may not be able to access the full amount of capital under the ELOC agreement if certain conditions are not met.
• The Series P Preferred Stock's redemption provisions could lead to further dilution.
• The proposed transactions require stockholder approval, and failure to obtain it could necessitate seeking alternative, potentially less advantageous, financing.
• The beneficial ownership limitation for C/M Capital (4.99%, potentially up to 9.99%) could still allow for significant influence over the company, and their interests may not align with other stockholders.

Future Outlook

The company is seeking stockholder approval for significant equity issuances that could provide substantial capital, but these issuances are expected to cause significant dilution to existing shareholders. The proceeds are intended for working capital and general corporate purposes. The company anticipates entering into the ELOC Agreement within 90 days of the Annual Meeting.

Management Comments

• "The Board of Directors has determined that the ELOC Agreement with C/M Capital is in the best interests of the Company and its stockholders because the right to sell shares to C/M Capital provides the Company with a reliable source of capital and the ability to access that capital when and as needed."
• "The ELOC Agreement will not affect the rights of the holders of outstanding Common Stock, but the sale of shares to C/M Capital pursuant to the terms of the ELOC Agreement will have a dilutive effect on the existing common stockholders, including the voting power and economic rights of the existing common stockholders."
• "We are therefore seeking stockholder approval for the issuance of more than 19.99% of our Common Stock outstanding prior to the execution of the ELOC Agreement to C/M Capital, pursuant to the ELOC Agreement."
• "We are therefore seeking stockholder approval for the issuance of more than 19.99% of our Common Stock outstanding prior to the execution of the Preferred Stock Purchase Agreement to C/M Capital, pursuant to the Preferred Stock Purchase Agreement and the Certificate of Designation."
• "The board of directors unanimously recommends that the stockholders vote FOR Proposal 1 to elect John Micek III as a Class II director."
• "The board of directors unanimously recommends that the stockholders vote FOR Proposal 2 to ratify the appointment of RBSM LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2026."
• "The board of directors unanimously recommends that the stockholders vote FOR Proposal 3 to pursuant to Nasdaq Listing Rule 5635(d), issue more than 19.99% of the Companys issued and outstanding shares of Common Stock to C/M Capital pursuant to the ELOC Agreement to be entered into between the Company and C/M Capital within 90 days after the Annual Meeting."
• "The board of directors unanimously recommends that the stockholders vote FOR Proposal 4 to, pursuant to Nasdaq Listing Rule 5635(d), issue more than 19.99% of the Companys issued and outstanding shares of Common Stock to C/M Capital pursuant to the Preferred Stock Purchase Agreement to be entered into between the Company and C/M Capital within 90 days after the Annual Meeting, including shares of Common Stock that are issuable upon redemption of the shares of Series P Preferred Stock to be issued and sold pursuant to the Preferred Stock Purchase Agreement."
• "The board of directors unanimously recommends that the stockholders vote FOR Proposal 5 to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in favor of Proposals 3 and 4."

Industry Context

StockSavvy.ai notes that Jaguar Health's reliance on equity financing, particularly through agreements that allow for significant share issuances at potentially discounted prices, is a common strategy for companies in the biotechnology sector facing capital needs. However, this approach often leads to substantial dilution for existing shareholders, a critical factor for investors to consider.

Corporate Governance

Related Party Transactions

• Insiders, including CEO Lisa A. Conte, CFO Carol Lizak, and several directors, participated in the Convertible Notes Financing in March 2025, purchasing $535,000 in notes and receiving warrants.
• Certain Insiders also participated in the Exchange Transaction in June 2025, acquiring $492,012 in Replacement Notes and receiving warrants.
• Transactions with Streeterville Capital, LLC and Iliad Research and Trading, L.P. (affiliates of CVP) involved various exchanges of common stock, preferred stock, and reductions in royalty interest balances, as well as amendments to notes and security agreements throughout 2025 and early 2026.
• The proposed ELOC and Preferred Stock Purchase Agreements are with C/M Capital Master Fund, LP, an accredited investor, which is a related party in the context of these significant transactions requiring stockholder approval.

Stakeholder Impact

• Shareholders will experience significant dilution if the proposed equity issuances are fully realized, potentially reducing their ownership percentage, voting power, and economic rights.
• The potential decrease in stock price due to discounted share sales and resales could negatively impact existing shareholders.
• Employees and management may see their equity holdings diluted, although they also stand to benefit from potential capital infusion and future growth.
• Creditors may be impacted by the increased share count and potential stock price volatility, although the capital raise aims to improve overall financial health.

Next Steps

• Stockholders to vote on the proposals at the 2026 Annual Meeting of Stockholders on May 22, 2026.
• If approved, the company intends to enter into the ELOC Agreement and Preferred Stock Purchase Agreement with C/M Capital within 90 days after the Annual Meeting.
• The company will file a registration statement with the SEC for the resale of shares purchased by C/M Capital under the ELOC Agreement.
• The company will file a certificate of designation for the Series P Preferred Stock with the Secretary of State of Delaware.

Key Dates

Recommendation

The company requires capital, and the proposed financing offers a path to secure it, but at the cost of significant dilution. While the board recommends approval, the substantial dilution risk warrants a cautious 'hold' recommendation. Investors should weigh the potential for future growth against the immediate impact on share value and ownership percentage.

Keywords

Jaguar Health, DEF 14A, Proxy Statement, Annual Meeting, Stockholder Approval, Equity Issuance, C/M Capital, ELOC Agreement, Preferred Stock, Dilution, Nasdaq Listing Rule, Director Election, Independent Auditor